# Study of the Safety and Efficacy of Nabiximols Oromucosal Spray Versus Placebo in Patients With Post-traumatic Stress Disorder

> **NCT04592159** · PHASE2,PHASE3 · WITHDRAWN · sponsor: **Jazz Pharmaceuticals**

## Conditions studied

- Post-Traumatic Stress Disorder

## Interventions

- **DRUG:** Nabiximols
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT04592159
- **Lead sponsor:** Jazz Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2021-02-01
- **Primary completion:** 2023-03
- **Final completion:** 2023-03
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** The decision to suspend this study was based upon evaluation of pandemic-related challenges impacting both clinical trial sites and potential participants. This suspension was initiated prior to site activation and participant recruitment.
- **Last updated:** 2022-06-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04592159

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04592159, "Study of the Safety and Efficacy of Nabiximols Oromucosal Spray Versus Placebo in Patients With Post-traumatic Stress Disorder". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT04592159. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*